New tumor model helps researchers treat pancreatic cancer

December 4, 2018 by Christie Delfanian, South Dakota State University
Postdoctoral research associate Mikhail Durymanov discusses the fluorescent images of the new 3D pancreatic tumor model with research scientist Liping Gu. This imaging confirmed that the spheroid tumors grown developed fibrous tissue. The new model will help researchers identify new drugs and drug delivery method to treat pancreatic cancer. Credit: South Dakota State University

Patients diagnosed with pancreatic cancer face a poor prognosis because the tumor forms dense scar-like tissue that is difficult for chemotherapy drugs to penetrate, but a new model may help researchers develop new therapies.

"More than 85 percent of form this fibrous ," explained Assistant Professor Joshua Reineke of the South Dakota State University Department of Pharmaceutical Sciences. However, most models used to test new drugs and drug delivery methods do not have this feature.

Reineke and his developed a 3-D in which the tumor surrounds itself with the fibrous tissue, known as a desmoplastic stroma reaction, through funding from the South Dakota Board of Regents. In addition, the researchers compared the with tumor tissue donated by patients undergoing surgery for pancreatic through collaboration with Avera Medical Group Oncology and Hematology.

"Every patient we met with consented, knowing the research would not help them, but future patients," Reineke said. "These patients have made a critical contribution." The study results are published in Translational Oncology.

"This model is a screening tool—it's not the golden ticket, but it can be used to identify things that work or don't work at an earlier stage," said Reineke. Postdoctoral research associate Mikhail Durymanov, whose expertise is in molecular and cellular biology, developed and characterized the models tested, with assistance from postdoctoral research associate Anastasia Permyakova and pharmacy student Christian Kroll.

Low survival rate

Pancreatic cancer is the fourth-most common cause of cancer-related deaths in the United States with a five-year survival rate of about 8 percent, according to Liz O'Neill, a certified nurse practitioner at Avera Medical Group Oncology and Hematology, who coordinated the study for Avera.

According to the South Dakota tumor registry, 117 patients were diagnosed with pancreatic cancer in 2015; this accounts for approximately 3 percent of the total number of cancers diagnosed. Nationally, pancreatic cancer diagnosis accounts for 3.2 percent of the total cancer diagnoses," O'Neill explained.

While doing about five years ago in Michigan, Reineke sought to develop nanoparticles to treat pancreatic cancer. However, he said, "The problem always came back to not having a way to prove the treatments could address the fibrotic issue because there were no good models to test that." That motivated Reineke, whose training included tissue engineering, to shift his work to developing a better model to evaluate potential therapies.

"We have not come nearly as far in [pancreatic cancer] research as we have with other cancers," O'Neill said.

Reineke agreed: "In the last 40 years, breast cancer went from a similar prognosis to a 95 percent survival rate, while pancreatic cancer has gone from 4 to 8 percent. A lot of what has worked in other cancers has not worked in pancreatic cancer and the unique scar tissue is one of the contributors to this ."

Reproducible cancer model

To evaluate the model, Reineke and his team compared the protein makeup of the scar-like tissue in the model and in the Avera patients' pancreatic tumor tissue.

"We can do the exact same assays on our model and the human tumor tissue, comparing the types, amount and structure of the proteins," he explained. "We see that we have a very nice fit—they are very similar."

In the experiments conducted, all the spheroid tumors grown developed . "This is very reproducible," Reineke explained. In addition, the researchers successfully transferred the tumor to a mouse model. "We can also do the animal study with the tumor and know it will have this robust scar tissue."

However, he noted, the model does not include an immune component that would account for the body's immune response to the cancer and the treatment. This may be an important limitation to the current model as some of the most significant advancements in cancer therapy have recently come from understanding and enhancing the involvement of a patient's in regulating tumors, Reineke explained. He and his team will work with Avera scientists to address some of the model's limitations, including possibly using patient tissues, rather than cell culture lines.

"Interactions with Avera clinicians and pathologists are very helpful in enabling this translational work," he said. "I appreciate Avera Health Systems' willingness to invest in basic research."

O'Neill said, "We know the surrounding stroma contributes to reduced penetration of drugs into the itself, so being able to mimic that in preclinical models is super important."

Reineke and his team are using the model to test therapies developed at SDSU and by other research groups across the nation and the world to find more effective ways to treat cancer.

Explore further: Suppression of DKK3 protein thwarts pancreatic tumor progression and prolongs survival

More information: Mikhail Durymanov et al. Subcutaneous Inoculation of 3D Pancreatic Cancer Spheroids Results in Development of Reproducible Stroma-Rich Tumors, Translational Oncology (2018). DOI: 10.1016/j.tranon.2018.10.003

Related Stories

Suppression of DKK3 protein thwarts pancreatic tumor progression and prolongs survival

October 24, 2018
Researchers at The University of Texas MD Anderson Cancer Center have shed new light on why pancreatic tumors are so resistant to therapy. The answer may lie in treating a protein found in the scar-type tissue called stroma ...

Turning cells against pancreatic cancer

October 26, 2018
Pancreatic cancer has a grim prognosis. It is usually detected after the disease has spread, and chemotherapy tends to do little to slow the cancer's growth. Even with treatment, most patients live only about six months after ...

New drug blocks pancreatic cancer growth in mice, study finds

September 25, 2018
A newly developed drug can prevent the most common type of pancreatic cancer from growing and spreading in laboratory mice, according to a study led by Cedars-Sinai.

Narrowing the gap toward precision medicine for pancreatic cancer

January 19, 2018
University of North Carolina Lineberger Comprehensive Cancer Center's Jen Jen Yeh, MD, is working to understand the complicated relationship between one of the deadliest cancers and the web of connective tissue that can surround ...

Researchers find potential key to unlocking the immune system in pancreatic cancer

August 6, 2018
A University of North Carolina Lineberger Comprehensive Cancer Center study may provide insights into how to overcome barriers to using immune-based treatments for pancreatic cancer, the third most deadly cancer in the United ...

Breath tests may allow for earlier detection of pancreatic cancer

July 18, 2018
Pancreatic cancer carries a very poor prognosis as most patients are diagnosed at an advanced stage. Now a new BJS (British Journal of Surgery) study indicates that breath analyses may help detect pancreatic cancer earlier, ...

Recommended for you

Researchers use computer model to predict prostate cancer progression

December 12, 2018
An international team of cancer researchers from Denmark and Germany have used cancer patient data to develop a computer model that can predict the progression of prostate cancer. The model is currently being implemented ...

Study examines disruption of circadian rhythm as risk factor for diseases

December 11, 2018
USC scientists report that a novel time-keeping mechanism within liver cells that helps sustain key organ tasks can contribute to diseases when its natural rhythm is disrupted.

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

New light-based technology reveals how cells communicate in human disease

December 11, 2018
Scientists at the University of York have developed a new technique that uses light to understand how cells communicate in human disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.